๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma : Incidence, treatment, and outcome

โœ Scribed by Brigitte C. Widemann; Frank M. Balis; Beate Kempf-Bielack; Stefan Bielack; Charles B. Pratt; Stefano Ferrari; Gaetano Bacci; Alan W. Craft; Peter C. Adamson

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
114 KB
Volume
100
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

The authors thank Dr. James Balow at the National Institute of Diabetes, and Digestive, and Kidney Disorders for helpful suggestions during the preparation of this article. This article is dedicated to the memory of Dr. Charles Pratt, who devoted his extraordinary career to the treatment of children with cancer and the development of more effective therapies for childhood cancers.

๐Ÿ“œ SIMILAR VOLUMES

High-dose methotrexate pharmacokinetics
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma
โœ Kristine R. Crews; Tiebin Liu; Carlos Rodriguez-Galindo; Ming Tan; William H. Me ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 161 KB

## Abstract ## BACKGROUND Highโ€dose methotrexate (HDMTX) is used frequently in combination regimens that include nephrotoxic chemotherapy. The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and

Influence of Methotrexate Dose Intensity
Influence of Methotrexate Dose Intensity on Outcome of Patients with High Grade Osteogenic Osteosarcoma : Analysis of the literature
โœ Stefan S. Bielack; Gerhard Beron; Kurt Winkler ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 62 KB ๐Ÿ‘ 2 views

trating type. Survival of patients with MHC may de- ## Influence of Methotrexate Dose pend on the stage of the tumor. ## Intensity on Outcome of Patients Clinically, we need an exact preoperative diagnosis for surgical treatment. Examination of cytokeratin with High Grade Osteogenic expression

High-dose methotrexate with citrovorum f
High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma
โœ Nikolay V. Dimitrov; James Egner; Ernie Balcueva; Leif G. Suhrland ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 272 KB ๐Ÿ‘ 3 views

The incidence of malignant mesothelioma has increased greatly in the last 40 years. Current and recent past exposure to asbestos is expected to substantially increase this incidence. We report nine cases of malignant mesothelioma which temporarily responded to treatment with high-dose methotrexate-c